Table 1 Baseline characteristics of patients involved in the study
n = 309 (FC = 101, SF = 82, LC = 126) | Mean ± SD | ||
|---|---|---|---|
Age (years) | FC | 62.9 ± 12.8 | |
SF | 63.6 ± 13.3 | ||
LC | 61.7 ± 11.4 | ||
Total | 62.6 ± 12.4 | ||
BMI (kg/m2) | FC | 23.1 ± 4.4 | |
SF | 22.7 ± 4.6 | ||
LC | 23.7 ± 3.8 | ||
Total | 23.2 ± 4.2 | ||
HD duration (months) | FC | 59.5 ± 55.0 | |
SF | 70.6 ± 78.9 | ||
LC | 71.4 ± 54.9 | ||
Total | 67.3 ± 62.1 | ||
Hb g/dL | FC | 10.7 ± 1.0 | |
SF | 11.0 ± 1.2 | ||
LC | 10.9 ± 0.9 | ||
Total | 10.9 ± 1.0 | ||
Pi mg/dL | FC | 6.172 ± 1.6339 | |
SF | 6.216 ± 1.2109 | ||
LC | 5.948 ± 1.4938 | ||
Total | 6.093 ± 1.4726 | ||
Gender | F | M | |
FC | 27.7% | 72.3% | |
SF | 37.8% | 62.2% | |
LC | 27.0% | 73.0% | |
DM/non-DM | Non-DM | DM | |
FC | 68.3% | 31.7% | |
SF | 62.2% | 37.8% | |
LC | 57.1% | 42.9% | |
Combined drug | FC | 65/101 | 64.4% |
SF | 57/82 | 69.5% | |
LC | 54/126 | 42.9% | |
Total | 176/311 | 57.0% | |